Loratadine

Generic Name: Loratadine

Brand Names: Alavert, Alavert D, Allerclear, Claritin, Claritin-D, Diphen, Loradamed, Wal-itin, Wal-itin D

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃ClN_₂O_₂

CAS Number: 79794-75-5

Unique Ingredient Identifier: 7AJO3BO7QN

Background: Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.

Indication: Loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.

Associated Conditions: Allergic Dermatologic Disorders, Allergic Reaction, Allergic Rhinitis (AR), Allergy to Tree Pollen, Chronic Urticaria, Common Cold, Epiphora, Eye pruritus, Fever, Nasal Congestion, Nasal Itching, Pain, Perennial Allergic Rhinitis (PAR), Pruritus, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Sensation of burning in the eyes, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine

Phase 3

Recruiting

Conditions: Common Cold

Interventions: Drug: Ibuprofen + Loratadine fixed dose
Drug: Ibuprofen
Drug: Loratadine

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-02

Lead Sponsor: Laboratorios Silanes S.A. de C.V.

Target Recruit Count: 177

Registration Number: NCT06531707

Locations: 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico

Gabapentin Versus Loratadine in Uremic Pruritus

Phase 4

Completed

Conditions: Pruritus
Uremia
Chronic Kidney Diseases

Interventions: Drug: Loratadine
Drug: Gabapentin

First Posted Date: 2023-03-02

Last Posted Date: 2023-03-16

Lead Sponsor: King Edward Medical University

Target Recruit Count: 64

Registration Number: NCT05750875

Locations: 🇵🇰
King Edward Medical University/Mayo Hospital, Lahore, Punjab, Pakistan

Loratadine for the Prevention of G-CSF-related Bone Pain

Phase 2

Not yet recruiting

Conditions: Stem Cell Transplant Complications

Interventions: Drug: Placebo
Drug: Loratadine

First Posted Date: 2022-06-16

Last Posted Date: 2024-06-12

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 78

Registration Number: NCT05421416

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy

Phase 3

Conditions: Vinca Alkaloid Adverse Reaction

Interventions: Drug: Diosmin/ Hesperidin
Drug: Loratadine

First Posted Date: 2022-02-17

Last Posted Date: 2022-02-17

Lead Sponsor: Ain Shams University

Target Recruit Count: 90

Registration Number: NCT05243706

Effect of Loratadine in Lymphangioleiomyomatosis

Phase 2

Conditions: Lymphangioleiomyomatosis

Interventions: Drug: Placebo 10mg/day added to rapamycin for 12 months
Drug: Loratadine

First Posted Date: 2022-01-13

Last Posted Date: 2022-01-27

Lead Sponsor: Institut d'Investigació Biomèdica de Bellvitge

Target Recruit Count: 62

Registration Number: NCT05190627

Locations: 🇪🇸
Hospital Puerta de Hierro, Madrid, Spain
🇪🇸
Hospital La Princes, Madrid, Spain
🇪🇸
Hospital Marqués de Valdecillas, Santander, Spain

and more 3 locations

Combined Antihistaminics Therapy in COVID 19 Patients

Phase 2

Completed

Conditions: Covid19

Interventions: Drug: Loratadine
Drug: Famotidine

First Posted Date: 2021-09-14

Last Posted Date: 2023-08-25

Lead Sponsor: Ain Shams University

Target Recruit Count: 214

Registration Number: NCT05043350

Locations: 🇪🇬
Nasr City Insurance Hospital, Cairo, Egypt

Antihistamines in Eosinophilic Esophagitis

Phase 2

Terminated

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Placebo
Drug: Famotidine
Drug: Loratadine

First Posted Date: 2020-01-30

Last Posted Date: 2022-12-20

Lead Sponsor: Mayo Clinic

Target Recruit Count: 1

Registration Number: NCT04248712

Locations: 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States

Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization

Early Phase 1

Recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Loratadine
Other: Placebo
Other: Questionnaire Administration

First Posted Date: 2019-12-26

Last Posted Date: 2023-08-07

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 70

Registration Number: NCT04211259

Locations: 🇺🇸
RWJBarnabas Health - Robert Wood Johnson University Hospital, New Brunswick, New Brunswick, New Jersey, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Loratadine for Improvement of Bone Pain in Patients With Chronic Granulocyte-Colony Stimulating Factor (G-CSF) Use

Phase 2

Terminated

Conditions: Bone Pain

Interventions: Drug: Loratadine
Drug: Placebo

First Posted Date: 2019-03-20

Last Posted Date: 2020-10-22

Lead Sponsor: University of Michigan

Target Recruit Count: 3

Registration Number: NCT03883386

Locations: 🇺🇸
The University of Michigan, Ann Arbor, Michigan, United States

Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)

Phase 3

Completed

Conditions: Rhinitis, Allergic

Interventions: Drug: Mometasone furoate nasal spray (MFNS)
Drug: Placebo tablet
Drug: Placebo nasal spray
Drug: Loratadine

First Posted Date: 2019-02-26

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 704

Registration Number: NCT03855228

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy